leukemia

[Leukemia] The authors review the most recent studies that provide experimental evidence showing how specific p21-activated kinases regulate the properties of leukemic stem cells and drug-resistant cells to initiate and maintain hematological malignancies.

[Critical Reviews in Oncology Hematology] Investigators review CD200 expression and its role in the immune evasion of non-B cell hematopoietic neoplasms and conclude that CD200 appears to be involved in the immune evasion of malignant cells, which could affect the survival of patients.

[ALX Oncology Holdings, Inc.] ALX Oncology Holdings, Inc. announced the first patient has been dosed in the Phase I/II ASPEN-05 study evaluating the combination of evorpacept with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia.

[Humanigen, Inc.] Humanigen, Inc. announced the first patient was dosed with lenzilumab in the Precision Approach to Chronic Myelomonocytic Leukemia (‘PREACH-M’) clinical trial.

[Leukemia & Lymphoma] Researchers investigated the efficiency and prognostic role of cytoplasmic CD79a antibody-gated multicolor flow cytometry in minimal residual disease detection in patients with B-ALL who received CD19-targeted chimeric antigen receptor (CAR) T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation.

[Nature Communications] The authors showed that miR-126 enhanced MYC activity through the SPRED1/PLK2-ERK-MYC axis. Genetic deletion of miR-126 significantly reduced acute myeloid leukemia rate and extended survival in CBFB-MYH11 knock-in mice.